Oncotelic Therapeutics, Inc. (OTLC)

Oncotelic Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Revenue	0.07	0	0	1.74	0
Cost of Revenue	0	0.01	0.06	0	0.06
Gross Profit	0.07	-0.01	-0.06	1.74	-0.06
Selling, General & Admin	0.57	4.85	5.47	5.02	2.94
Research & Development	0.06	0.76	3.66	4.3	1.37
Other Operating Expenses	0.07	0.53	0	0	0
Operating Expenses	0.63	5.61	9.13	9.33	4.31
Operating Income	-0.56	-9.72	-9.13	-7.58	-4.31
Interest Income	0	0	0	0	0
Interest Expense	1.04	2.97	2	2	0.75
Other Expense / Income	6.6	-17.37	-0.61	0.39	1.58
Pretax Income	-8.21	4.68	-10.52	-9.97	-6.64
Income Tax	-0.3	-13.14	0.88	1.53	0.75
Net Income	-7.9	17.82	-11.39	-11.5	-7.39
Shares Outstanding (Basic)	396	384	303	88	60
Shares Outstanding (Diluted)	396	457	303	88	60
Shares Change	-13.37%	50.88%	244.02%	46.93%	60.96%
EPS (Basic)	-0.02	0.05	-0.04	-0.13	-0.12
EPS (Diluted)	-0.02	0.04	-0.04	-0.13	-0.12
Free Cash Flow	-1.32	-1.45	-4.43	-2.81	-2.28
Free Cash Flow Per Share	-0.00	-0.00	-0.01	-0.03	-0.04
Gross Margin	100.00%	-	-	100.00%	-
Operating Margin	-806.96%	-	-	-435.69%	-
Profit Margin	-11290.13%	-	-	-660.65%	-
Free Cash Flow Margin	-1887.21%	-	-	-161.53%	-
Effective Tax Rate	-	-281.04%	-	-	-
EBITDA	-0.56	-5.06	-9.06	-7.22	-4.25
EBITDA Margin	-806.96%	-	-	-414.77%	-
Depreciation & Amortization	0	0.01	0.06	0.36	0.06
EBIT	-	-5.08	-9.13	-7.58	-4.31
EBIT Margin	-	-	-	-435.69%	-

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.